Display options
Cite
Matter A. Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biol Med. 2015;12(4):316-27doi: 10.7497/j.issn.2095-3941.2015.0079.
Matter, A. (2015). Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer biology & medicine, 12(4), 316-27. https://doi.org/10.7497/j.issn.2095-3941.2015.0079
Matter, Alex. "Bridging academic science and clinical research in the search for novel targeted anti-cancer agents." Cancer biology & medicine vol. 12,4 (2015): 316-27. doi: https://doi.org/10.7497/j.issn.2095-3941.2015.0079
Matter A. Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biol Med. 2015 Dec;12(4):316-27. doi: 10.7497/j.issn.2095-3941.2015.0079. PMID: 26779369; PMCID: PMC4706519.
Copy Download .nbib Format: NLM
Share it on

Cancer Biol Med. 2015 Dec;12(4):316-27. doi: 10.7497/j.issn.2095-3941.2015.0079.

Bridging academic science and clinical research in the search for novel targeted anti-cancer agents.

Cancer biology & medicine

Alex Matter

Affiliations

  1. Experimental Therapeutics Center & D3, ASTAR, Singapore 138669, Singapore.

PMID: 26779369 PMCID: PMC4706519 DOI: 10.7497/j.issn.2095-3941.2015.0079

Abstract

This review starts with a brief history of drug discovery & development, and the place of Asia in this worldwide effort discussed. The conditions and constraints of a successful translational R&D involving academic basic research and clinical research are discussed and the Singapore model for pursuit of open R&D described. The importance of well-characterized, validated drug targets for the search for novel targeted anti-cancer agents is emphasized, as well as a structured, high quality translational R&D. Furthermore, the characteristics of an attractive preclinical development drug candidate are discussed laying the foundation of a successful preclinical development. The most frequent sources of failures are described and risk management at every stage is highly recommended. Organizational factors are also considered to play an important role. The factors to consider before starting a new drug discovery & development project are described, and an example is given of a successful clinical project that has had its roots in local universities and was carried through preclinical development into phase I clinical trials.

Keywords: Drug discovery; drug development; targeted anti-cancer agents; translational R&D

References

  1. Med Oncol. 2015 Jun;32(6):626 - PubMed
  2. Nat Rev Drug Discov. 2011 Jun;10(6):428-38 - PubMed
  3. Nat Rev Gastroenterol Hepatol. 2015 Aug;12(8):437-45 - PubMed
  4. Cancer Gene Ther. 2015 Sep;22(9):417-30 - PubMed
  5. Nature. 2012 Apr 29;485(7397):195-200 - PubMed
  6. Leukemia. 2015 May;29(5):1104-14 - PubMed
  7. Nat Med. 2015 Jun;21(6):581-90 - PubMed
  8. Nat Med. 2001 May;7(5):548-52 - PubMed
  9. PLoS One. 2012;7(11):e48372 - PubMed
  10. Nat Biotechnol. 2008 Jan;26(1):37-53 - PubMed
  11. Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242 - PubMed
  12. Br J Cancer. 2003 Feb 10;88(3):366-72 - PubMed
  13. Blood Cancer J. 2012 Oct 19;2:e95 - PubMed
  14. Blood. 2008 Mar 1;111(5):2505-15 - PubMed
  15. Nat Biotechnol. 2014 Jul;32(7):621-5 - PubMed
  16. N Engl J Med. 2015 May 21;372(21):2006-17 - PubMed
  17. Nat Med. 2009 Oct;15(10):1149-52 - PubMed
  18. Clin Transl Oncol. 2012 Aug;14(8):619-29 - PubMed
  19. Nat Rev Drug Discov. 2014 Aug;13(8):588-602 - PubMed
  20. Nat Rev Clin Oncol. 2013 May;10(5):267-76 - PubMed
  21. Nat Rev Drug Discov. 2002 Jul;1(7):493-502 - PubMed
  22. Nat Rev Drug Discov. 2015 Jul;14(7):475-86 - PubMed
  23. Nat Rev Drug Discov. 2014 Jun;13(6):419-31 - PubMed
  24. Nat Rev Cancer. 2009 Sep;9(9):655-64 - PubMed
  25. Oncogene. 2016 Apr 7;35(14):1743-9 - PubMed
  26. Nat Rev Cancer. 2006 Sep;6(9):674-87 - PubMed
  27. Nat Rev Cancer. 2005 Sep;5(9):689-98 - PubMed
  28. Nat Rev Drug Discov. 2012 Feb 10;11(3):201-14 - PubMed
  29. Nat Rev Drug Discov. 2011 Aug 01;10 (8):591-600 - PubMed
  30. Nature. 2012 Aug 30;488(7413):665-9 - PubMed
  31. Nat Rev Drug Discov. 2011 Aug 01;10(8):559-60 - PubMed
  32. Nat Genet. 2014 Jun;46(6):573-82 - PubMed
  33. Nat Rev Clin Oncol. 2015 Dec;12(12):693-704 - PubMed
  34. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  35. Mod Pathol. 2013 Jul;26(7):1004-12 - PubMed
  36. Nat Rev Drug Discov. 2010 Apr;9(4):253-4 - PubMed
  37. Sci Rep. 2015 Aug 17;5:13110 - PubMed
  38. Nature. 2012 Aug 30;488(7413):660-4 - PubMed
  39. Br J Cancer. 2014 Dec 9;111(12):2214-9 - PubMed
  40. J Clin Oncol. 2012 Apr 1;30(10):1030-3 - PubMed
  41. Nature. 2012 May 16;486(7403):400-4 - PubMed
  42. Ther Adv Respir Dis. 2015 Jun;9(3):97-104 - PubMed
  43. Emerg Microbes Infect. 2012 Sep;1(9):e27 - PubMed
  44. Nat Rev Drug Discov. 2014 Jan;13(1):15-6 - PubMed
  45. Nat Rev Cancer. 2014 May;14(5):299-313 - PubMed
  46. Nat Immunol. 2005 Mar;6(3):314-22 - PubMed
  47. Nat Rev Drug Discov. 2015 Jan;14(1):17-28 - PubMed
  48. N Engl J Med. 2015 Jul 2;373(1):23-34 - PubMed
  49. Nat Rev Microbiol. 2010 Dec;8(12 Suppl):S7-16 - PubMed
  50. Nat Rev Drug Discov. 2012 Dec;11(12):909-22 - PubMed
  51. Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12649-54 - PubMed
  52. Expert Opin Drug Discov. 2012 Jun;7(6):457-61 - PubMed
  53. Nat Clin Pract Oncol. 2008 Jan;5(1):24-31 - PubMed
  54. Eur J Cancer. 2005 Aug;41(12):1751-7 - PubMed
  55. J Clin Oncol. 2015 Mar 20;33(9):975-7 - PubMed
  56. Nat Rev Gastroenterol Hepatol. 2012 May 29;9(7):365 - PubMed
  57. Oncogene. 2016 Apr 28;35(17):2197-207 - PubMed
  58. Mol Biol Rep. 2014 Aug;41(8):5375-84 - PubMed

Publication Types